$MSSTF News
Last published 3y ago
- 3y agoMSSTFMindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine CompoundsGlobeNewswireTORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and
- 3y agoMSSTFMindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023GlobeNewswireTORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and
- 3y agoMSSTFMindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic TherapeuticsGlobeNewswireTORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company") today issued a letter to shareholders from James Lanthier, Chief Executive Officer of
- 3y agoMSSTFMindset Pharma To Defend Against Lawsuit Filed By Reunion NeurosciencesGlobeNewswireTORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and
- 3y agoMSSTFMindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales PartnershipGlobeNewswireTORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and
- 3y agoMSSTFMindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin AnalogsGlobeNewswireTORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation
- 3y agoMSSTFMindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug CandidatesGlobeNewswireTORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation
- 3y agoMSSTFMindset Pharma to Participate in Upcoming Conferences in December 2022GlobeNewswireTORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and
- 3y agoMSSTFMindset Pharma CEO, James Lanthier Issues Letter to ShareholdersGlobeNewswireTORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company") today issued a letter to shareholders from James Lanthier, Chief Executive Officer of
- 3y agoMSSTFMindset Pharma and PharmAla Biotech Enter into Exclusive Sales AgreementGlobeNewswireVANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla")(CSE:MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class
- 3y agoMSSTFMindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade PsilocybinGlobeNewswireTORONTO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation
- 3y agoMSSTFMindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug CandidateGlobeNewswireTORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation
- 4y agoMSSTFMindset Pharma Announces Poster Presentations at Two Upcoming Scientific ConferencesGlobeNewswire5th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston, MA on October 31st Neuroscience 2022 by the Society of Neuroscience in San Diego, CA on November 13th TORONTO, Oct. 27, 2022 (GLOBE
- 4y agoMSSTFMindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug PortfolioGlobeNewswireTORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat
- 4y agoCSE:MSETCYBNMSSTFCybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based CompoundsBusiness Wire– Provides access to large catalog of compounds complementary to Company's preclinical assets – – Strengthens drug discovery and development platform to build future potential novel drug candidates – – Supports broad intellectual propert
- 4y agoCYBNMSSTFMindset Pharma Provides Strategic Intellectual Property License to CybinGlobeNewswireTORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatri
- 4y agoMSSTFMindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014GlobeNewswireTORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat
- 4y agoMSSTFMindset Pharma Files National Patents Protecting Family 1 Application in 16 Different CountriesGlobeNewswireTORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psyched
- 4y agoMSSTFMindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic CompoundsGlobeNewswireTORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychede
- 4y agoMSSTFMindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022GlobeNewswireTORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychede
- 4y agoMSSTFMindset Pharma CEO, James Lanthier, Issues Letter to ShareholdersGlobeNewswireTORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychede
- 4y agoMSSTFMindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System DisordersGlobeNewswireTORONTO, July 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma Announces Development of Novel, Optimized, Intranasal FormulationGlobeNewswireTORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic-inspired
- 4y agoMSSTFMindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to PsilocybinGlobeNewswireTORONTO, June 22, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System DisordersGlobeNewswireTORONTO, June 10, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma to Participate in Upcoming Conferences in June 2022GlobeNewswireTORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicine
- 4y agoMSSTFMindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014GlobeNewswireTORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma to Participate in Upcoming Conferences in May 2022GlobeNewswireTORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFEmerging Markets Report: More Tools in the ToolboxGlobeNewswireAn Emerging Markets Sponsored Commentary ORLANDO, Fla., April 22, 2022 (GLOBE NEWSWIRE) -- Sometimes as we continue our coverage of Mindset Pharma Inc. (Mindset) (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) it feels as if we are covering TWO unique stories.
- 4y agoMSSTFMindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate CompoundsGlobeNewswireTORONTO, April 19, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicine
- 4y agoMSSTFMindset Pharma to Participate in Upcoming Conferences in April 2022GlobeNewswireTORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicine
- 4y agoMSSTFEmerging Markets Report: Love LettersGlobeNewswireAn Emerging Markets Sponsored Commentary ORLANDO, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- In the world of emergent small cap companies there are a few things we love to see. Chief among them are positive shareholder letters from senior management
- 4y agoMSSTFMindset Pharma CEO, James Lanthier, Issues Letter to ShareholdersGlobeNewswireTORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicine
- 4y agoMSSTFMindset Pharma to Participate in Upcoming Investor Conferences in March 2022GlobeNewswireTORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicine
- 4y agoMSSTFMindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo SolutionsGlobeNewswireTORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFEmerging Markets Report: Healing Minds, Expanding MarketsGlobeNewswireAn Emerging Markets Sponsored Commentary ORLANDO, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Important news from Mindset Pharma Inc. (Mindset) (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF), a drug discovery and development company focused on creating next-gene
- 4y agoMSSTFMindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific StrategyGlobeNewswireTORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its "Microdosing" CompoundsGlobeNewswireMindset's Family 3 of next-generation psilocybin compounds have demonstrated low levels of activity at the 5-HT2A receptor and long half lives Advancing compounds into additional Proof of Concept preclinical studies to measure daily take-home viabil
- 4y agoMSSTFEmerging Markets Report: A Meeting of the MindsGlobeNewswireAn Emerging Markets Sponsored Commentary ORLANDO, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Breaking news from Mindset Pharma Inc. (Mindset) (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF), a drug discovery and development company focused on creating next-gen
- 4y agoMSSTFMindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014GlobeNewswireTORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFThe McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic MedicinesGlobeNewswirePRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. (Mindset) (CSE:MSET) (FSE: 9DF) (OTCQB:M
- 4y agoCSE:MSETMSSTFThe McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic MedicinesBusiness WireThe McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. (Mindset) (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) today announce a collaboration that will suppo
- 4y agoMSSTFMindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022GlobeNewswireTORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma Recaps 2021 Milestones and HighlightsGlobeNewswireEvolving Pipeline of Psychedelic Compounds Focused on Improved Efficacy and Safety Advancing MSP-1014 as First Lead Drug Clinical Candidate to IND-Enabling Studies TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET)
- 4y agoMSSTFMindset Pharma Announces Filing of International Patent Application Covering its Family 3 "Microdose" CompoundsGlobeNewswireTORONTO, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma to Participate in Citi's Psychedelic Drug Call Series on January 6thGlobeNewswireTORONTO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset Pharma to Participate in Stifel GMP's The Future of Healthcare Conference on December 8thGlobeNewswireTORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 4y agoMSSTFMindset to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6thGlobeNewswireTORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 5y agoMSSTFMindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021GlobeNewswireTORONTO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines
- 5y agoMSSTFMindset Pharma Reports Fiscal Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswire--Evolving Pipeline of Psychedelics Compounds Focused on Improved Efficacy and Safety Advancing MSP-1014 as First Lead Drug Clinical Candidate to IND-Enabling Studies Developing Robust Patent Portfolio for Next-Generation Compounds